Ekso Bionics price target lowered to $9.50 from $15 at Lake Street

Lake Street lowered the firm’s price target on Ekso Bionics (EKSO) to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell “well below” the firm’s expectations, attributable to the company’s Enterprise Health business. While the firm does not believe investors “should become overly concerned with the company’s Q2 results,” it recognizes improvements “may not be readily evident prior to the company requiring additional funds.”